All News
Impact of regulatory warning on JAK inhibitors
The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using JAKi in patients with certain risk factors, e.g., ≥65 years, at increased risk of MACE, current smoker or past smoker and at increased risk of cancer, should other alternative treatment be available. So, how has this warning impacted on JAKi development and use?
Read Article
Is RA always preceded by clinically suspect arthralgia? Cohort 650+ pts CSA = 83 pts no CSA = 616 pts
Pts w/ no CSA: -older -more frequent acute onset of symptoms -higher SJC -increased CRP -less ACPA+ No sure how accounted for memory bias
#EULAR2024 @RheumNow POS1030 https://t.co/dJeN41ax5P
Aurelie Najm AurelieRheumo ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024
Peter Nash drpnash ( View Tweet)
FAPI PET/CT entheseal & synovial fibroblast activation predicts PsA in high risk PsO better than MUS @RheumNow #EULAR2024 https://t.co/uqmEvMg9WN
Peter Nash drpnash ( View Tweet)
more evidence in PsA - switch MOA rather than cycle within class failed first TNF @RheumNow #EULAR2024 https://t.co/hf2UB5MXEy
Peter Nash drpnash ( View Tweet)
opposing point of view especially in males at 3 years !@RheumNow #EULAR2024 https://t.co/CXxIScQbFD
Peter Nash drpnash ( View Tweet)
#wasup in #GCA?
#upadacitinib +RCT in #temporal #arteritis LBA0001
Residual #inflammation in 1/3 of pts at 6 mo #Rx w #TCZ on repeat TA Bx
OP0621
#PMR cases
#Leflunomide beats #MTX for
#pred sparing
⬇️relapses
But MTX dose was low
POS0280
#EULAR2024 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
New #JAKi #disease #results
#Baricitinib in #alopecia #areata esp 4mg/d
#Upadacitinib in Crohn’s
#Upa in #polyarticular #JIA & kid #PsA
+RCT of UPA in #GCA
Awaiting results of #SLE
With #deucravicitinib & UPA #RCTs
#EULAR2024 @eular_org @RheumNow
Janet Pope Janetbirdope ( View Tweet)
#Behcet’s #syndrome is increasing in the UK
? ⬆️ Detection
? Changing population demographics
? Other reasons
Poster discussion POS0258
#EULAR2024 @RheumNow @eular_org
@Pr1yankaC https://t.co/SEzmJnFMhM
Links:
Janet Pope Janetbirdope ( View Tweet)
When would I use
#Aclasta vs #Prolia since #denosumab has LESS #fractures
▶️younger women with #osteoporosis requiring Rx due to long safety
▶️less wearing off when stopping it
▶️noncompliant Pts as prolia reverses effect when dose is missed
@RheumNow #EULAR2024 @eular_org https://t.co/0RTGx0sCTd
Janet Pope Janetbirdope ( View Tweet)
Agree!
Liz Volkmann said it straight
Unsustainable RCTs in ILD trials in #scleroderma
Why
Can’t recruit
~same pool of early #dcSSc design RCT
UNETHICAL a to have a progressing #scleroderma-ILD Pt on failed background #MMF + placebo for 1 yr
🙏🏻 #EULAR2024 @RheumNow @eular_org https://t.co/29oFEazwmM
Janet Pope Janetbirdope ( View Tweet)
I think if we’re worried about JAK inhibitor safety, we need to be doing it right.
I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read:
https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg
Links:
David Liew drdavidliew ( View Tweet)
🗓️ Our abstract on psychosocial determinants of health in #RheumatoidArthritis will be presented at #EULAR2024
📹 Watch my video on @RheumNow for a sneak preview!
📍 Join me to hear more on #PARE Poster Tour IV, Friday 14th June, 12:00 - 13:00 CEST
https://t.co/rDTJVukD6j
Mrinalini Dey DrMiniDey ( View Tweet)
➡️POS0591 Are there sex differences in risk & outcomes of stroke in patients with #RA?
📈Stroke risk in RA increased compared to general population
🫀Not fully explained by traditional risk factors or AF
📊Stroke-related mortality differs in women vs men
@RheumNow #EULAR2024
Mrinalini Dey DrMiniDey ( View Tweet)
POS0592 Increased overall & cause-specific mortality in population-based cohort of people with incident #RA
Higher mortality in RA vs gen pop but this has decreased after 2000 & better 10-year survival
Severe causes of mortality incl cardiac higher in RA
EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
POS1035 FVC & risk of lung transplant & mortality in #RAILD
50% pts had FVC % predicted decline in ~6.5yrs
2/3 identified groups more strongly assoc w transplant or ILD-related death than INBUILD definition ➡️marked heterogeneity in ILD progression
#EULAR2024 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
important session worth reading the full recommendations - TNF tick of approval @RheumNow #EULAR2024 https://t.co/ORDocVie11
Peter Nash drpnash ( View Tweet)